SOPHiA GENETICS (SOPH) Guggenheim Inaugural Global Healthcare Innovation Conference summary

Company overview and platform evolution

• Founded in 2011, the platform launched in 2015 and now supports over 700 hospitals and labs in 70 countries.

• Over 1.8 million genomic profiles have been computed, with 30,000 processed monthly.

• The platform is cloud-based, leveraging AI for data analysis and supporting multiple data modalities, with genomics as the core focus.

• Customers use in-house sequencers and upload data securely to the platform, which operates on a usage-based payment model.

• The company emphasizes customer-centricity and a land-and-expand strategy to grow application volume.

Recent product launches and adoption trends

• Launched a liquid biopsy application in Q2, signing 18 customers across 10 countries and building a pipeline of 50 potential new customers.

• Introduced MSK-IMPACT, a comprehensive genomic profiling solution, with strong early demand.

• Signed major clients like Tennessee Oncology, reflecting growing adoption of in-house precision medicine.

• Partnerships with NVIDIA and Microsoft enhance scalability and data compute capabilities.

• Achieved a high customer NPS score of 75, indicating strong satisfaction.

Financial performance and outlook

• Q3 2024 revenue reached $15.9 million, with gross margins above 73%.

• Computed 91,000 genomic profiles in the quarter, with a 39% year-on-year improvement in cash burn.

• Holds over $95 million in cash and targets profitability by 2026.

• Clinical volume grew 17% and revenue 12% year-over-year, excluding COVID-related activity.

• Biopharma strategy shifted to focus on smaller, repeat deals due to changing pharma budgets.